Security record · archived quarter
BMRN
BioMarin Pharmaceutical Inc. · Healthcare · Biotechnology
19Tracked holders
—Δ holders
53.80MShares held
$4.43BReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 137 | +4 | 146.98M | $8.41B | +11 | −6 |
| Q1 2026 | 135 | -4 | 142.18M | $8.03B | +5 | −10 |
| Q4 2025 | 138 | +3 | 154.93M | $9.20B | +4 | — |
| Q3 2025 | 23 | -1 | 108.93M | $5.90B | — | −2 |
| Q2 2025 | 22 | -2 | 113.78M | $6.25B | — | −2 |
| Q1 2025 | 21 | 0 | 70.58M | $4.99B | +1 | −1 |
| Q4 2024 | 21 | +1 | 67.83M | $4.46B | +1 | — |
| Q3 2024 | 19 | 0 | 57.19M | $4.02B | +2 | −2 |
| Q2 2024 | 19 | — | 53.80M | $4.43B | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 18.79M | — | $1.55B | 1.1% | n/c | 1 | SEC ↗ |
| 2 | Dodge & Cox ✦ | 13.93M | — | $1.15B | 0.7% | n/c | 1 | SEC ↗ |
| 3 | Viking Global Investors ✦ | 7.06M | — | $581.54M | 2.2% | n/c | 1 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 3.62M | — | $297.99M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Elliott Investment Management ✦ | 3.50M | — | $288.18M | 2.9% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 3.20M | — | $262.96M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 3.20M | — | $262.96M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 1.12M | — | $92.10M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Millennium Management ✦ | 1.12M | — | $92.10M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 983.34K | — | $80.96M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 983.34K | — | $80.96M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 557.85K | — | $45.93M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 557.85K | — | $45.93M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 340.45K | — | $28.03M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 268.37K | — | $22.10M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 268.37K | — | $22.10M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Soros Fund Management ✦ | 156.05K | — | $12.85M | 0.4% | n/c | 1 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 116.20K | — | $9.57M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 55.37K | — | $4.56M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 55.37K | — | $4.56M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 55.37K | — | $4.56M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 55.37K | — | $4.56M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Marshall Wace ✦ | 42.74K | — | $3.52M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Bridgewater Associates ✦ | 34.98K | — | $2.88M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Fisher Asset Management ✦ | 13.42K | — | $1.11M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Wellington Management ✦ | 6.92K | — | $569,476 | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Wellington Management ✦ | 6.92K | — | $569,476 | 0.0% | n/c | 1 | SEC ↗ |
| 28 | GAMCO Investors ✦ | 5.32K | — | $437,584 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 549 holders, 183.01M shares, $10.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API